Lupin is currently trading at Rs. 986.20, up by 7.70 points or 0.79% from its previous closing of Rs. 978.50 on the BSE.
The scrip opened at Rs. 982.55 and has touched a high and low of Rs. 994.30 and Rs. 976.00 respectively. So far 72409 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1034.55 on 17-Aug-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 1021.00 and Rs. 960.50 respectively. The current market cap of the company is Rs. 44862.25 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.88% and 12.91% respectively.
Lupin and Mylan N.V. have launched Nepexto, biosimilar etanercept, in the German market. Nepexto is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis from the age of 2 years, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents from the age of 6 years. Nepexto is approved for all therapeutic indications of the reference product Enbrel.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
